| CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma (NCT06479356) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2024-08-15 |
| Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus (NCT06297408) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2024-03-01 |
| Relmacabtagene Autoleucel in Hematologic Malignancies (NCT06142188) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2023-12-28 |
| Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (NCT06093841) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2023-11-03 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma (NCT06149169) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2023-08-17 |
| CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus (NCT05765006) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2023-02-24 |
| Relmacabtagene Autoleucel in Patients With LBCL (NCT06142175) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2022-12-28 |
| CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia (NCT05727683) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2022-04-28 |
| Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL (NCT05259813) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2022-02-28 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma (NCT04718883) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2021-01-13 |
| CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma (NCT04812691) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2020-07-10 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma (NCT04089215) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2019-06-11 |